Pittsburgh, Pennsylvania
Colorectal cancer clinical trials in Pittsburgh, PA
37 colorectal cancer studies are recruiting participants at sites in Pittsburgh as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Pittsburgh at a glance
- 37 studies are recruiting at a site in Pittsburgh.
- By phase: Phase 1 (9), Phase 1/2 (9), Phase 2 (5), Phase 2/3 (1), Phase 3 (8), No phase (4), Observational (1). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (22), university, hospital or other (12), government (3).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Pittsburgh
Basic details from each study's public record (the 30 most recently updated of 37). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Allegheny General Hospital · West Penn Hospital
- Registry record
- NCT05863195 · updated
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UPMC Hillman Cancer Center ( Site 2024)
- Registry record
- NCT06997497 · updated
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT07228832 · updated
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- No phase
- Ages 45 to 70
- All sexes
- Sponsor
- NRG Oncology
- Study site
- UPMC-Presbyterian Hospital
- Registry record
- NCT05080673 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Mercy Hospital
- Registry record
- NCT05174169 · updated
Distance-Based Exercise to Preserve Function and Prevent Disability
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
- Registry record
- NCT07059884 · updated
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT07397338 · updated
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Allegheny General Hospital · West Penn Hospital
- Registry record
- NCT05673148 · updated
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
- Registry record
- NCT06662786 · updated
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
- Registry record
- NCT06750094 · updated
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Allegheny General Hospital Cancer Institute · Hillman Cancer Center
- Registry record
- NCT07284849 · updated
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT05803382 · updated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- University of Pittsburgh Medical Center
- Registry record
- NCT06710756 · updated
The Cancer of the Pancreas Screening-5 CAPS5)Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Johns Hopkins University
- Study site
- University of Pittsburgh
- Registry record
- NCT02000089 · updated
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT06654037 · updated
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Criterium, Inc.
- Study site
- UPMC / University of Pittsburgh Medical Center
- Registry record
- NCT06992258 · updated
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kura Oncology, Inc.
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT06026410 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- University of Pittsburgh Medical Center, Hillman Cancer Center
- Registry record
- NCT05919264 · updated
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Bicara Therapeutics
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT04429542 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- University of Pittsburgh Medical Center
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #32
- Registry record
- NCT05176483 · updated
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT05877599 · updated
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Phanes Therapeutics
- Study site
- University of Pittsburgh Medical Center (UPMC)
- Registry record
- NCT05482893 · updated
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Allegheny Health Network
- Registry record
- NCT06128551 · updated
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Aktis Oncology, Inc.
- Registry record
- NCT07020117 · updated
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- NSABP Foundation Inc
- Study sites
- Allegheny General Hospital · Magee-Womens Hospital of UPMC
- Registry record
- NCT07058012 · updated
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Phase 1/2
- From 12 months, up to 30 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Children's Hospital of Pittsburgh of UPMC
- Registry record
- NCT04851119 · updated
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Kahr Bio Australia Pty Ltd
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT07235293 · updated
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT05691491 · updated
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Coherus Oncology, Inc.
- Study site
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center
- Registry record
- NCT06657144 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Ask about studies near Pittsburgh
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
91 studies recruiting across 61 cities.
Philadelphia
48 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections